An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Who May Qualify: - Men diagnosed with hemophilia B aged 18 or older - FIX activity ≤2% - Absense of FIX inhibitor - ≥150 previous exposure days of treatment with FIX concentrates Who Should NOT Join This Trial: - Any diseases of blood and hematopoietic organs other than hemophilia B - A history of any gene therapy, including ANB-002 - Diagnosed HIV-infection, not controlled with anti-viral therapy - Active HBV or HCV infection - Anti-AAV5 antibodies - Any active systemic infections or recurrent infections requiring systemic therapy - Any other disorders associated with severe weakened immune system - Relevant hepatic disorders or conditions that can be a symptom of existing liver disorder - Malignancies with less than 5 years of remission Always talk to your doctor about whether this trial is right for you.